{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-012607","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.393194+00:00","generated_at":"2026-06-20T11:53:48.502623+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pliant Therapeutics: Bexotegrast 320 mg shows significant FVC increase in IPF Phase 2a trial","bullets":["320 mg group met primary/safety endpoints; no drug-related severe/serious adverse events over 12 weeks.","Mean FVC increase of +29.5 mL from baseline vs placebo decline of 110.7 mL (+140 mL vs placebo, p<0.05 at all timepoints).","No bexotegrast-treated patients had FVCpp decline ≥10%; QLF progression slowed vs placebo (0.20% vs 1.46%).","PRO-C3 and integrin beta-6 biomarkers reduced at 4 and 12 weeks (p<0.01 and p<0.0001 vs placebo).","Phase 2b trial planned for mid-2023; final 24-week data from 320 mg cohort expected Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-012607","json":"https://secwatch.observer/filing/0001193125-23-012607.json","markdown":"https://secwatch.observer/filing/0001193125-23-012607.md","text":"https://secwatch.observer/filing/0001193125-23-012607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523012607/0001193125-23-012607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523012607/d418942d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:53:48.502623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}